Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial

Abstract In this post hoc subgroup analysis of 200 patients enrolled in China from the phase III PHOENIX trial (N = 838, NCT01855750), addition of ibrutinib to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) did not improve event‐free survival (EFS) versus placebo+R...

Full description

Bibliographic Details
Main Authors: Jun Zhu, Xiaonan Hong, Yu Qin Song, Brendan Hodkinson, Sriram Balasubramanian, Songbai Wang, Qingyuan Zhang, Yuankai Shi, Huiqiang Huang, Huilai Zhang, Yan Zhu, Stephen Martin Shreeve, Steven Sun, Ze Wang, Xiaocan Wang, Yue Fan, Wyndham Wilson, Jessica Vermeulen
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:eJHaem
Subjects:
China
DLBCL
ibrutinib
previously untreated
Online Access:https://doi.org/10.1002/jha2.517

Internet

https://doi.org/10.1002/jha2.517

Similar Items